Use of JAK inhibitors in the management of myelofibrosis: a revision of the British Committee for Standards in Haematology Guidelines for Investigation and Management of Myelofibrosis 2012.

Use of JAK inhibitors in the management of myelofibrosis: a revision of the British Committee for Standards in Haematology Guidelines for Investigation and Management of Myelofibrosis 2012.

Show other versions (1)

Bibliographic Details
Main Authors:	Reilly, J, McMullin, M, Beer, P, Butt, N, Conneally, E, Duncombe, A, Green, A, Mikhaeel, G, Gilleece, M, Knapper, S, Mead, A, Mesa, R, Sekhar, M, Harrison, C
Format:	Journal article
Language:	English
Published:	2014

Similar Items

Use of JAK inhibitors in the management of myelofibrosis: A revision of the British Committee for Standards in Haematology Guidelines for Investigation and Management of Myelofibrosis 2012
by: Reilly, J, et al.
Published: (2014)

Guideline for the diagnosis and management of myelofibrosis.
by: Reilly, J, et al.
Published: (2012)

Guideline for the diagnosis and management of myelofibrosis
by: Reilly, J, et al.
Published: (2012)

Diagnosis and evaluation of prognosis of myelofibrosis: a British Society for Haematology Guideline
by: McLornan, DP, et al.
Published: (2023)

Practical management of patients with myelofibrosis receiving ruxolitinib.
by: Harrison, C, et al.
Published: (2013)

A physician survey on the application of the British Society for Haematology guidelines for the diagnosis and management of myelofibrosis in the UK
by: Harrison, C, et al.
Published: (2019)

Modification of British Committee for Standards in Haematology diagnostic criteria for essential thrombocythaemia.
by: Harrison, C, et al.
Published: (2014)

Defining disease modification in myelofibrosis in the era of targeted therapy
by: Pemmaraju, N, et al.
Published: (2022)

Allogeneic Stem Cell Transplantation for Myelofibrosis in 2012
by: Mclornan, D, et al.
Published: (2012)

Rapid emergence of chronic lymphocytic leukemia during JAK2 inhibitor therapy in a patient with myelofibrosis
by: Sousos, N, et al.
Published: (2020)

Allogeneic stem cell transplantation for myelofibrosis in 2012.
by: McLornan, D, et al.
Published: (2012)

The UK Myeloproliferative Neoplasm Registry for Myelofibrosis (UK-MPN-MF registry)
by: Butt, N, et al.
Published: (2019)

Modification of British committee for standards in haematology diagnostic criteria for essential thrombocythaemia
by: Harrison, C, et al.
Published: (2014)

Symptomatic benefit of momelotinib in patients with myelofibrosis: results from the SIMPLIFY phase III studies
by: Mesa, RA, et al.
Published: (2023)

MOMENTUM: momelotinib vs danazol in patients with myelofibrosis previously treated with JAKi who are symptomatic and anemic
by: Verstovsek, S, et al.
Published: (2021)

In utero origin of myelofibrosis presenting in adult monozygotic twins
by: Sousos, N, et al.
Published: (2022)

Recent advances in therapies for primary myelofibrosis
by: Vainchenker, W, et al.
Published: (2023)

Spliceosome mutations are common in MPN-associated myelofibrosis with RBC-transfusion-dependence and correlate with response to pomalidomide
by: Chowdhury, O, et al.
Published: (2018)

Long-term treatment with pacritinib on a compassionate use basis in patients with advanced myelofibrosis
by: Harrison, C, et al.
Published: (2023)

Ruxolitinib is effective in patients with intermediate-1 risk myelofibrosis: a summary of recent evidence
by: Harrison, C, et al.
Published: (2016)

SRSF2-P95H decreases JAK/STAT signaling in hematopoietic cells and delays myelofibrosis development in mice
by: Willekens, C, et al.
Published: (2023)

A guideline for the diagnosis and management of polycythaemia vera. A British Society for haematology guideline
by: McMullin, M, et al.
Published: (2018)

Enhanced engraftment of human myelofibrosis stem and progenitor cells in MISTRG mice
by: Lysenko, V, et al.
Published: (2020)

A single-cell approach to unraveling abnormal megakaryocyte differentiation and function in myelofibrosis
by: Psaila, B, et al.
Published: (2017)

Childhood idiopathic myelofibrosis : a case report and review of literature.
by: Zulkifli, Noor Fadzillah, et al.
Published: (2009)

Absence of mutations in the key megakaryocyte transcriptional regulator FOG-1 in patients with idiopathic myelofibrosis.
by: Fisher, C, et al.
Published: (2004)

Fedratinib combined with ropeginterferon alfa-2b in patients with myelofibrosis (FEDORA): study protocol for a multicentre, open-label, Bayesian phase II trial
by: McIlroy, G, et al.
Published: (2025)

A retrospective real-world study of the current treatment pathways for myelofibrosis in the United Kingdom: the REALISM UK study
by: Mead, AJ, et al.
Published: (2022)

Ruxolitinib therapy followed by reduced-intensity conditioning for hematopoietic cell transplantation for myelofibrosis: Myeloproliferative Disorders Research Consortium 114 study
by: Gupta, V, et al.
Published: (2018)

Somatic point mutations in RUNX1/CBFA2/AML1 are common in high-risk myelodysplastic syndrome, but not in myelofibrosis with myeloid metaplasia
by: Steensma, D, et al.
Published: (2004)

Somatic point mutations in RUNX1/CBFA2/AML1 are common in high-risk myelodysplastic syndrome, but not in myelofibrosis with myeloid metaplasia.
by: Steensma, D, et al.
Published: (2005)

Therapeutic activity of GARP:TGF-β1 blockade in murine primary myelofibrosis
by: Lecomte, S, et al.
Published: (2023)

RAS-pathway mutations are common in patients with ruxolitinib refractory/intolerant myelofibrosis: molecular analysis of the PAC203 cohort
by: O'Sullivan, JM, et al.
Published: (2023)

Pacritinib versus best available therapy for the treatment of myelofibrosis irrespective of baseline cytopenias (PERSIST-1): an international, randomised, phase 3 trial
by: Mesa, R, et al.
Published: (2017)

Determining the recommended dose of pacritinib: results from the PAC203 dose-finding trial in advanced myelofibrosis
by: Gerds, AT, et al.
Published: (2020)

A proinflammatory stem cell niche drives myelofibrosis through a targetable galectin-1 axis
by: Li, R, et al.
Published: (2024)

Single-cell analyses reveal megakaryocyte-biased hematopoiesis in myelofibrosis and identify mutant clone-specific targets
by: Psaila, B, et al.
Published: (2020)

A retrospective real world evidence study to review the current treatment pathways for myelofibrosis from across the United Kingdom (the REALISM UK study)
by: Mead, A, et al.
Published: (2019)

Modification of the histone landscape with JAK inhibition in myeloproliferative neoplasms
by: Greenfield, G, et al.
Published: (2020)

Spliceosome mutations are common in persons with myeloproliferative neoplasm-associated myelofibrosis with RBC-transfusion-dependence and correlate with response to pomalidomide
by: Chowdhury, O, et al.
Published: (2020)